https://orcid.org/0000-0003-4681-888X
Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (27)
Elena Dolmatova, Nida Waheed, Brian Michael Olson, Sagar A. Patel & Anant Mandawat. (2023) The Intersection of Prostate Cancer and Hypertension: a Call to Action. Current Treatment Options in Oncology 24:7, pages 892-905.
Crossref
Crossref
James Fradin, Felix J. Kim, Grace L. Lu-Yao, Eugene Storozynsky & William K. Kelly. (2023) Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer. Cancers 15:8, pages 2316.
Crossref
Crossref
Li Gu, Xurui Li & Wentao Liu. (2023) Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis. Frontiers in Endocrinology 14.
Crossref
Crossref
Yusuf Ilker Comez. (2023) Retreatment Plan Success through Patient Health Awareness, Health Behavior, and Access to Doctor after a Focal Therapy Procedure for Prostate Cancer. American Journal of Health Behavior 47:1, pages 116-129.
Crossref
Crossref
Alice Dragomir, Nawar Touma, Jason Hu, Sylvie Perreault & Armen G. Aprikian. (2023) Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk. Journal of the National Comprehensive Cancer Network 21:2, pages 163-171.
Crossref
Crossref
Marco Oderda, Oscar Bertetto, Giulia Barbera, Giorgio Calleris, Marco Falcone, Claudia Filippini, Alessandro Marquis, Giancarlo Marra, Gabriele Montefusco, Federica Peretti & Paolo Gontero. (2023) Appropriateness and complications of androgen deprivation therapy for prostate cancer: Can we do better? A retrospective observational analysis from a referral center. Urologia Journal 90:1, pages 100-108.
Crossref
Crossref
Antonio Cicione, Antonio Nacchia, Alessandro Guercio, Carmen Gravina, Antonio Franco, Maria Chiara Grimaldi, Giorgia Tema, Riccardo Lombardo, Andrea Tubaro & Cosimo De Nunzio. (2023) Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries. Prostate Cancer and Prostatic Diseases.
Crossref
Crossref
Andrew J Hamblen, James W Bray, Mohan Hingorani & John M Saxton. (2023) Physical activity and dietary considerations for prostate cancer patients: future research directions. Proceedings of the Nutrition Society, pages 1-7.
Crossref
Crossref
Steven Tisseverasinghe, Marwan Tolba, Fred Saad, Gwenaëlle Gravis, Boris Bahoric & Tamim Niazi. (2022) Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?. Journal of Clinical Oncology 40:36, pages 4173-4177.
Crossref
Crossref
D. A. Andreev & A. A. Zavyalov. (2022) Cardiovascular safety of hormone therapy for prostate cancer. Cancer Urology 18:3, pages 85-91.
Crossref
Crossref
Vera Vaz Ferreira, Inês Ângelo, Boban Thomas & Arjun K Ghosh. (2022) Cardiovascular complications of treatment for prostate cancer. British Journal of Hospital Medicine 83:11, pages 1-12.
Crossref
Crossref
Rachel B. Forster, Anders Engeland, Rune Kvåle, Vidar Hjellvik & Tone Bjørge. (2022) Association between medical androgen deprivation therapy and long‐term cardiovascular disease and all‐cause mortality in nonmetastatic prostate cancer. International Journal of Cancer 151:7, pages 1109-1119.
Crossref
Crossref
Cosimo DE NUNZIO, Cristian FIORI, Ferdinando FUSCO, Andrea GREGORI, Vincenzo PAGLIARULO & Filippo ALONGI. (2022) Androgen deprivation therapy and cardiovascular risk in prostate cancer. Minerva Urology and Nephrology 74:5.
Crossref
Crossref
Yu-Hsuan Joni Shao, Jian-Hua Hong, Chun-Kai Chen & Chao-Yuan Huang. (2022) Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan. Prostate Cancer and Prostatic Diseases.
Crossref
Crossref
Patrick Davey & Kyriacos Alexandrou. (2022) Assessment and Mitigation of Cardiovascular Risk for Prostate Cancer Patients: A Review of the Evidence. International Journal of Clinical Practice 2022, pages 1-13.
Crossref
Crossref
J. Lehmann, C. W. Kluike, A. Haider, K. S Haider, S. Baumann, M. Flesch, M. Gedamke & D. Kägebein. (2021) Einflussfaktoren bei der Wahl der Androgendeprivationstherapie für Patienten mit hormonsensitiven ProstatakarzinomFactors influencing the choice of androgen deprivation therapy for patients with hormone-sensitive prostate cancer. Der Urologe 61:2, pages 173-182.
Crossref
Crossref
David J. Reeves & Vijay U. Rao. (2022) Update on cancer therapy-induced atherosclerosis. Current Opinion in Cardiology Publish Ahead of Print.
Crossref
Crossref
Gunhild von Amsberg, Holger Thiele & Axel Merseburger. (2021) Kardiovaskuläre Komplikationen unter Androgenentzugstherapie: Vorteil für Gonadotropin-Releasing-Hormon-Antagonisten? Ein UpdateCardiovascular side effects in patients undergoing androgen deprivation therapy: superiority of gonadotropin-releasing hormone antagonists? An update. Der Urologe 60:11, pages 1450-1457.
Crossref
Crossref
Renato D. Lopes, Celestia S. HiganoSusan F. SlovinAdam J. NelsonRobert Bigelow, Per S. SørensenChiara MelloniShaun G. GoodmanChristopher P. Evans, Jan Nilsson, Deepak L. BhattNoel W. ClarkeTine K. Olesen, Belinda T. Doyle-OlsenHenriette KristensenLauren ArneyMatthew T. RoeJohn H. AlexanderMirjam Mol-Arts, Samreen Mansor-Lefebvre, Konstantin Zubovskiy, Allan Blemings, Klaus Dugi, Gerald Bloomfield, Chris Kontos, Adam DeVore, Dedrick Jordan, Bradley Kolls, Robin Matthews, Rajendra Mehta, Thomas J. Povsic, Michael Morse, Kenneth W. Mahaffey, Susan Halabi, Darryl Leong, Laurence Klotz, Neil Fleshner, Godfrey Jansz, Jonathan Giddens, Russell Egerdie, Joseph Chin, Joseph Zadra, Richard Casey, Jean Simard, Tamim Niazi, André-Guy Martin, Marek Babjuk, Jaroslav Hajek, Jiri Klecka, Jiri Kubes, Jan Schraml, Jitka Jakesova, Jaroslav Vanasek, Bohuslav Melichar, Heikki Seikkula, Manouar Samir Abdiche, Marc Colombel, Philippe Debourdeau, Gregoire Robert, Arnauld Villers, Guillaume Ploussard, Benjamin Pradere, Franck Bruyere, Jean-Luc Descotes, Idir Ouzaid, Alexander Winter, Herbert Hanitzsch, Herbert Sperling, Ralf Eckert, Peter Hammerer, Elke Stagge, Florian Seseke, Silvio Szymula, Aristotelis Bamias, Anastasios Thanos, Konstantinos Hatzimouratidis, Charalambos Mamoulakis, Haralabos Kalofonos, Elzbieta Oszukowska, Katarzyna Madziarska, Jacek Fijuth, Mateusz Obarzanowski, Boris Alekseev, Vagif Atduev, Dmitri Pushkar, Evgeniy Veliev, Alexander Zyryanov, Sergey Petrov, Evgeny Kopyltsov, Vadim Kozlov, Ladislav Macko, Jozef Dubravicky, Richard Polak, Obaidullah Mir, Marek Vargovcak, Ivan Mincik, Jan Kliment, Frederico Goncalves, Juraj Mikulas, Roman Sokol, Michal Korcek, Jozef Marko, Viktor Kovacik, Igor Milichovsky, Pavol Dubinsky, John Lazarus, Sanjay Dixit, Euan Green, Rajaguru Srinivasan, Danish Mazhar, Yeung Ng, Naveed Sarwar, Craig Herman, Frederick Snoy, Robert Given, Ronald Suh, David Lipsitz, James Bailen, Lawrence Gervasi, Idalia Acosta, Laurence Belkoff, Ning Wu, Jeffrey Frankel, Lawrence Karsh, Bryant Poole, David Lieber, Jason Engel, Mohamed Bidair, Steven Rosenberg, Paul Sieber, Adam Perzin, Susan Kalota, Amar Singh, Ralph Henderson, Jeffrey Wayne, Moben Mirza, Richard D’Anna, Fredrick Wolk, Osvaldo Padron, Kathryn Bylow, Jonathan Rubenstein, Benjamin Gartrell, Michael Schwartz, Kalpesh Patel, Ajit Maniam, Thomas Keane, Michael Goodman, Charles Bane, Michael Chung, Stephen Savage, Edward Uchio, Son Nguyen, William Aronson, Rakesh Khanna & Carlton Barnswell. (2021) Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation 144:16, pages 1295-1307.
Crossref
Crossref
DEEPTHI C DENNY, YOGAVADULA SS, VIJAY R, MOHAMED FARDAN, DIVYA SARA IYPE & ABI MAHESHWARAN K. (2021) CARDIOVASCULAR RISK ASSOCIATED WITH ANDROGEN DEPRIVATION THERAPY IN ADVANCED PROSTATE CANCER. Asian Journal of Pharmaceutical and Clinical Research, pages 6-9.
Crossref
Crossref
Friedemann Zengerling, Joachim J Jakob, Stefanie Schmidt, Joerg J Meerpohl, Anette Blümle, Christine Schmucker, Benjamin Mayer & Frank Kunath. (2021) Degarelix for treating advanced hormone-sensitive prostate cancer. Cochrane Database of Systematic Reviews 2021:8.
Crossref
Crossref
Alessandro Sciarra, Gian Maria Busetto, Stefano Salciccia, Francesco Del Giudice, Martina Maggi, Felice Crocetto, Matteo Ferro, Ettore De Berardinis, Roberto Mario Scarpa, Francesco Porpiglia, Luca Carmignani, Rocco Damiano, Walter Artibani & Giuseppe Carrieri. (2021) Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies. Frontiers in Endocrinology 12.
Crossref
Crossref
Azariyas A. Challa, Adam Christopher Calaway, Jennifer Cullen, Jorge Garcia, Nihar Desai, Neal L. Weintraub, Anita Deswal, Shelby Kutty, Ajay Vallakati, Daniel Addison, Ragavendra Baliga, Courtney M. Campbell & Avirup Guha. (2021) Cardiovascular Toxicities of Androgen Deprivation Therapy. Current Treatment Options in Oncology 22:6.
Crossref
Crossref
Patrick Davey & Mike G. Kirby. (2020) Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice. World Journal of Urology 39:2, pages 307-315.
Crossref
Crossref
Fred Saad & Neal D. Shore. (2021) Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Therapeutic Advances in Medical Oncology 13, pages 175883592199858.
Crossref
Crossref
Fabrizio Fontana, Monica Marzagalli, Marina Montagnani Marelli, Michela Raimondi, Roberta Moretti & Patrizia Limonta. (2020) Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions. International Journal of Molecular Sciences 21:24, pages 9511.
Crossref
Crossref
Courtney M. Campbell, Kathleen W. Zhang, Andrew Collier, Mark Linch, Adam C. Calaway, Lee Ponsky, Avirup Guha & Arjun K. Ghosh. (2020) Cardiovascular Complications of Prostate Cancer Therapy. Current Treatment Options in Cardiovascular Medicine 22:12.
Crossref
Crossref